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Abstract
Objective: To estimate the prevalence of gestational complications 
and perinatal outcomes in women with and without hemoglobino-
pathies. 
Method: This is a cross-sectional study with a quantitative approach, 
performed from 110 medical records of pregnant women who un-
derwent prenatal, childbirth, postpartum and perinatal care in a gyne-
cology and obstetrics service of the University Hospital at the Federal 
University of Mato Grosso do Sul, Brazil, between 2010 and 2011. 
Results: Gestational complications in women with and without 
hemoglobinopathies in the variables: obstetric (preterm labor, pre-
eclampsia, ruptured membranes for more than six hours (17.06 times; 
12.19 times; 4.27 times respectively); clinical: urinary tract infection, 
heart failure, severe anemia (2.97 times; 12.6 times; 9.75 times, respec-
tively), and perinatal: cesarean delivery, neonatal infection; the new-
born in the neonatal intensive care unit; fetal death, stillbirth (1.57 
times; 39.00 times; 12.19 times; 12.9 times; 9.75 times; respectively) 
were higher in the presence of hemoglobinopathies. 
Conclusion: The pregnancy outcomes of women with hemoglobi-
nopathies, perinatal and their newborns showed a higher prevalence 
of complications than women without this change.
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Introduction
In general, hemoglobinopathies are the most fre-
quent monogenic diseases in the population. They 
are characterized by mutations or deletions in the 
genes encoding the alpha (α) and beta (β) globin 
chains of the human hemoglobin molecule (Hb) 
[1]. There are many hemoglobin variants described. 
However, the structural variants of hemoglobins S 
and C (HbS and HbC) are the most common and 
clinically significant [2].
The HbS is a mutation in the β globin gene, which 
is the substitution of glutamic acid (GAG) for valine 
(GTG) and it causes the hemoglobin physicochemical 
changes [3]. This structural change in HbS when in 
deoxygenation situations is organized in long poly-
mers and change the morphology of the red blood 
cell, becoming elongated and sickle-shaped [4].
Sickle cell disease (SCD) is a generic term used 
to define a group of genetic diseases that have the 
predominance of HbS as a common characteristic 
[5], originated in Africa and due to the forced mi-
gration of slaves the disease was brought to the 
Americas [6].
The most severe form of SCD is the sickle cell ane-
mia (HbSS) occurring more often in homozygous. 
SCD may also occur in double heterozygous when 
HbS is associated to other abnormal Hb able to ge-
nerate Hb variants (HbC, HbD) or in the interaction 
with thalassemia [7].
HbC is also originated from a mutation in the 
β globin gene. However, the GAG is replaced by 
lysine (AAG). In this case, there is also a change 
in hemoglobin structure making it more prone to 
crystallization [4]. In Brazil, double heterozygous 
for HbS and HbC, hemoglobinopathy SC (HbSC), 
is the second demonstration in frequency after ho-
mozygous for HbS.
According to data from the National Neonatal 
Screening Program (PNTN), there are about 200,000 
carriers of sickle cell trait and 3,500 children with 
sickle cell disease or a sick child for every 1,000 
live births are born each year in Brazil [8]. Thus, 
the prevalence of heterozygotes for HbS is higher 
in the North and Northeast (6% to 10%), while in 
the South and Southeast its prevalence is lower (2% 
to 3%) [9].
In Brazil, a review literature study with original 
articles showed a heterogeneous distribution of the 
sickle cell disease and trait with a higher prevalence 
in the Northeast and lowest in the South, while 
pointing out the lack of publications in the northern 
region [10].
In the Central West region of Brazil, in the Mato 
Grosso do Sul state (MS), a study conducted from 
2000 to 2005 showed genotypic changes in 2624 
(1.38%) newborns (NB). Among those with altered 
genotypes, 2,602 (99.16%) newborns had sickle cell 
trait, and 16 (0.61%) had the genotype Hb SS [11].
Another study carried out from 2006 to 2010 
showed that with increased coverage of the scree-
ning program in 78 municipalities in the state of 
Mato Grosso do Sul, 3,011 (99.05%) were HbAS, an 
asymptomatic form of the disease, 20 (0.66%) were 
diagnosed with HbSS, eight (0.26%) had results for 
HbSC and one NB (0.03%) had HbSD association 
[12].
In a study of pregnant women in high-risk preg-
nancy clinic of the University Hospital of the Federal 
University of Mato Grosso do Sul (HU/UFMS), poin-
ted out that of the 215 pregnant women analyzed, 
there were 17.7% with anemia and 4.7% detected 
hemoglobinopathies [13].
Before considered aspects as well as the existing 
gap in the literature on the subject, this study ai-
med to estimate the prevalence of gestational and 
perinatal outcomes of women with hemoglobino-
pathies.
Method
This is a cross-sectional study with a quantitative 
approach, performed from medical records of preg-
nant women who underwent prenatal, childbirth, 
postpartum and perinatal care in the Gynecology 
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and Obstetrics Service of the University Hospital at 
the Federal University of Mato Grosso do Sul (HU/
UFMS), located in the city of Campo Grande/MS, 
from November 2010 to August 2011.
The data were collected from medical records of 
110 pregnant women who divided into two groups: 
group 1 (n=32) with hemoglobinopathies (HbAS, 
hbAC, HbSS, β-thalassemia) and group 2 (n=78) 
without hemoglobinopathies (HbAA).
The inclusion criteria for both groups were: diag-
nosis of hemoglobinopathies performed by hemog-
lobin electrophoresis; and the pre-natal, delivery 
and puerperal monitoring had been carried out at 
the University Hospital.
Records of women of Indian origin, under 18, 
who did not have complete prenatal care as out-
patients studied, whose records did not report the 
results of hemoglobin electrophoresis test and data 
obstetric and perinatal outcome were excluded from 
the study.
An instrument with the clinical, obstetrical and 
perinatal variables was designed for data collec-
tion, objects of this study: a) clinical: Urinary Tract 
Infection (UTI), heart failure, severe anemia, and 
pneumonia. b) Obstetric: pre-term labor, membrane 
broken time more than 6 hours, preeclampsia, ab-
normal amniotic fluid, delayed intrauterine growth, 
two or more abortions in obstetric history, stillbirth 
in obstetric history and gestational diabetes melli-
tus. c) Perinatal: cesarean delivery, fetal death (defi-
ned as death of the product design, which occurred 
prior to complete expulsion or extraction from the 
mother, regardless of the time of pregnancy), mis-
carriage, stillbirth (originates from the stillbirth) [14], 
Apgar score at 5 minutes less than seven, low birth 
weight of infants (birth weight measured within the 
first 60 minutes less than 2,500g), a small newborn 
(NB) for its gestational age (SGA) (classification of 
newborns, according to their degree of nutritio-
nal status, according to Lubchenko curve, which 
measures the relationship between birth weight 
and gestational age, considered SGA) [15], neona-
tal infection, infants in neonatal intensive care unit 
(NICU) and puerperal infection.
Statistical analysis was performed using the Epi-
Info software version 3.4.3 and Biostat. The eva-
luation of the association between the presence 
or absence of hemoglobinopathies and obstetric, 
clinical and perinatal variables of pregnancies was 
performed using the chi-square test or Fisher’s exact 
test when one of the contingency table cells had a 
lower frequency than five. In both tests used, the 
significance level of 5% was adopted.
This study met the national and international 
standards of ethics in research involving human 
beings, approved in its ethical and methodological 
aspects by the Ethics Committee on Research of the 
Federal University of Mato Grosso do Sul, according 
to the National Council of Health Nº 466/2012 [16], 
under Opinion Nº 1,781/2010.
Results
There were 110 medical records analyzed of preg-
nant women with and without hemoglobinopathies 
assisted at the Gynaecology and Obstetrics Clinic 
of the HU/UFMS to research clinical, obstetric and 
perinatal complications in pregnancies.
In the obstetric variables, the preterm labor, pree-
clampsia and membrane broken time higher than 
six hours were (17.06, 12.19, 4.27 respectively) times 
more prevalent in women of pregnancies with he-
moglobinopathies (Table 1).
Table 1.  Relationship between obstetric variables 
and the presence of hemoglobinopathies 
in pregnancies analyzed in the period from 
2010 to 2011. Campo Grande/MS, Brazil, 
2016 (n=110).
Obstetric 
variables
Hemoglobinopathies
PR1
(CI 95%)
p2
Present 
(n=32)
Absent 
(n=78)
n % n %
Preterm 
labor
7 21.9 1 1.3
17.06 
(2.19-133.14)
0.001
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The clinical variables of urinary tract infection, 
heart failure, severe anemia were (2.97, 12.6, 9.75 
respectively) times more prevalent in pregnancies of 
women with hemoglobinopathies (Table 2).
Perinatal variables of Cesarean childbirth, NB in 
the NICU; Neonatal Infection, Fetal death are (1.57; 
12.19; 39.00; 12.19 respectively) times more preva-
lent in pregnancies of women with hemoglobino-
pathies (Table 3).
Discussion
The sickle cell disease can influence the course of 
pregnancy since in 50% of pregnancies there are 
infections and the systems more affected there are 
the respiratory and urinary [17]. In a study develo-
ped in Jamaica with pregnant women with sickle 
Obstetric 
variables
Hemoglobinopathies
PR1
(CI 95%)
p2
Present 
(n=32)
Absent 
(n=78)
n % n %
Membrane 
broken for 
more than 6 
hours
7 21.9 4 5.1
4.27 
(1.34-13.57)
0.013
Pre-eclampsia 5 15.6 1 1.3
12.19 
(1.48-100.25)
0.008
Changes in 
AF
4 12.5 7 9.0
1.39 
(0.44-4.43)
0.727
IUGR 3 9.4 8 10.3
0.91
(0.26-3.23)
1.000
Two or more 
abortions in 
the OP
3 9.4 5 6.4
1.46 
(0.37-5.76)
0.689
Stillbirth 
in OP
1 3.1 1 1.3
2.44 
(0.16-37.79)
0.499
Gestational 
Diabetes 
mellitus
7 21.9 9 11.5
1.90 
(0.77-4.65)
0.232
1: PR = Prevalence ratio, 2: Fisher Exact Test. AF: Amniotic 
fluid, IUGR: Intra Uterine Growth Retardation, 
OP: Obstetric past
Table 2.  Relationship between clinical variables and 
the presence of hemoglobinopathies in 
pregnancies analyzed in the period from 
2010 to 2011. Campo Grande/MS, Brazil, 
2016 (n=110).
Clinical 
variables
Hemoglobinopathies
PR1
(CI 95%)
p2
Present 
(n=32)
Absent 
(n=78)
n % n %
Urinary tract 
infection 21 65.6 11 14.1
2.97 
(1.60-5.53)
0.0012
Heart 
failure
5 15.6 1 1.3
12.19 
(1.48-100.25)
0.0083
Severe 
anemia
4 12.5 1 1.3
9.75
(1.13-83.90)
0.0252
Pneumonia 4 12.5 - - - 0.0062
1: PR = Prevalence ratio, 2: Chi-square Test, 3: Fisher Exact 
Test. UTI: Urinary Tract Infection, PMN: Pneumonia.
Table 3.  Relationship between perinatal variables 
and the presence of hemoglobinopathies 
in pregnancies analyzed in the period from 
2010 to 2011. Campo Grande/MS, Brazil, 
2016 (n=110).
Perinatal 
variables
Hemoglobinopathies
PR1
(CI 95%)
p
Present 
(n=32)
Absent 
(n=78)
n % n %
Cesarean 
delivery 20 62.5 31 39.7
1.57 
(1.07-2.31)
0.0302
Fetus death 5 15.6 1 1.3
12.19 
(1.48-100.25)
0.0083
Abortion 9 28.1 18 23.1
1.22 
(0.61- 2.42)
0.5762
Stillbirth 4 12.5 1 1.3
9.75
(1.13-83.90)
0.0253
Apgar of 51 
min <7
2 6.3 1 1.3
4.88 
(0.46-51.89)
0.2023
NB with 
weight 
<2.500g
5 15.6 15 19.2
0.81
( 0.32-2.05)
0.6562
NB SGA 1 3.1 - - - 0.2913
Neonatal 
infection
16 50.0 1 1.3
39.00 
(5.40-281.90)
0.0013
NB in NICU 5 15.6 1 1.3
12.19 
(1.48-100.25)
0.0083
Infecção 
puerperal
2 6.3 - - - 0.0833
1: PR, 2: Chi-square Test, 3: Fisher Exact Test. NB: newborn, 
NB SGA: Newborn in Small for Gestational Age, RN in 
NICU: Newborn in the Neonatal Intensive Care Unit.
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cell anemia, the researchers found that 57% of 
pregnancies progressed without complications [18]. 
For these reasons, preventive actions involving early 
diagnosis are necessary to minimize injuries in this 
segment of the population [19, 20].
In this study, the preterm labor was 17.06 more 
prevalent among women with pregnancies with he-
moglobinopathies compared to those without he-
moglobinopathies. These findings corroborated the 
studies in Cuba and Jamaica, which received high 
frequency of preterm births [18, 21, 22].
Thus, in this study, the prevalence of prolonged 
rupture of membranes was four times higher, and 
preeclampsia was 12 times higher in pregnancies of 
women with hemoglobinopathies compared with 
those without it. Other studies have found high ra-
tes of preeclampsia among women with sickle cell 
disease [23, 24].
It was also found that UTI was twice as prevalent 
among women with pregnancies with hemoglobi-
nopathies compared with those without it. Similar 
results have been reported in the literature [5, 22]. 
It should be emphasized that in sickle cell disease 
there is an increased risk for urinary tract infections. 
When they occur during pregnancy, they may con-
tribute to other complications such as miscarriage or 
preterm labor [21]. In a study conducted in Tanzania 
with 149 pregnant women, there was an excess risk 
of maternal deaths by sickle cell disease compared 
with those who had not. The infections were the 
most common cause of 82% and 32% without the 
disease [25].
Severe anemia was 9.75 times more prevalent in 
women with pregnancies with hemoglobinopathies 
compared to those without it. The lower survival 
of red blood cells is the main cause of anemia in 
patients with sickle cell disease, which stems from 
hemolytic anemia with increased indirect bilirubin, 
erythroid hyperplasia of the bone marrow and ele-
vated reticulocyte [4].
As for perinatal variables, it was found that ce-
sarean section was more frequent among women 
with hemoglobinopathies with 1.57 times more 
prevalent in pregnancies of women with hemoglo-
binopathies when compared with those who had 
not. A fact discussed in a cohort study, in which 
the proportion of caesarean sections was increased 
both in the group of women with sickle cell disease 
and the group of carriers of sickle cell trait, with no 
significant difference between them [22].
The fetal death was approximately 15.6 times 
more prevalent in women in pregnancies with he-
moglobinopathies compared to those without it. 
Research developed in a high-risk pregnancy service 
of a university tertiary referral hospital in southeas-
tern Brazil showed that 12% of stillbirths occurred 
in women with sickle cell disease and 25% of them 
occurred due to severe placental insufficiency [22].
This study showed that the prevalence of neona-
tal infection was 39.6 times more prevalent among 
newborns of women with hemoglobinopathies. 
There was a gap in the literature on neonatal in-
fection and perinatal outcome in newborns of these 
women. However, prematurity situations, hospita-
lization in the NICU, low birth weight, intrauteri-
ne growth restriction associated with the mother´s 
complications, especially preterm rupture of amnio-
tic membranes and UTI, are factors that can increa-
se the risk of infection to these infants [21, 22].
Studies show that pregnant women with hemog-
lobinopathies being more subject to various com-
plications, such as infections, preeclampsia [6, 22], 
worsening anemia, worsening of bone lesions and 
retinopathy [22] and miscarriages. [4] Complications 
that affect the fetus or newborns in these cases 
are delayed intrauterine growth, low birth weight, 
prematurity and stillbirth [5, 22].
The prevalence in the Neonatal Intensive Care 
Unit was 12.19 times higher among newborns to 
women with hemoglobinopathies compared to the 
others. Although prematurity is prevalent in this di-
sease, it cannot be considered the only factor that 
may cause the newborn to the Neonatal Intensive 
Care Unit [21, 22].
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In this study, there was no association observed 
between the presence of hemoglobinopathies with 
the variables “two or more abortions in obstetric 
past,” “stillbirth in obstetrical past,” “delayed in-
trauterine growth,” “Gestational Diabetes Mellitus” 
and “amniotic fluid change.” A study conducted 
at the University Hospital of Southeastern Brazil, 
tertiary, was also no difference found in the occu-
rrence of gestational diabetes when there was a 
comparison with sickle cell disease and pregnant 
women with sickle cell trait. However, the delay in 
intrauterine growth was significantly more frequent 
in the group with sickle cell disease [22].
In a systematic review of maternal and perinatal 
outcomes of pregnant women with sickle cell di-
sease it was concluded that the risks are higher for 
pregnant women with sickle cell anemia - HbSS, 
and in low-income countries they are more suscep-
tible to morbidity and mortality, in which access an-
tenatal care with specialized multidisciplinary team 
are not properly systemized and implemented [23].
The limiting factors of this study were the pre-
sence of some characteristics complications of he-
moglobinopathies, as the painful crises. Because 
this complication is not part of the clinical picture 
of pregnancies of women without hemoglobino-
pathies, it was decided not to examine them to 
avoid bias.
Conclusion
It was observed that women with hemoglobino-
pathies pregnancies have a higher prevalence of 
higher obstetric, clinical and perinatal complica-
tions compared to those without this condition. 
The complications identified were preterm birth, 
preterm labor, preeclampsia, UTI. In newborns of 
pregnant women with sickle cell disease, there was 
a prevalence of newborns in the NICU and Neonatal 
deaths.
The knowledge of the complications that can af-
fect women with hemoglobinopathies during preg-
nancy and puerperal period, and their newborns, 
enables the health professional for more effective 
assistance for prevention and early identification as 
well as the decision-making of such cases.
This study highlights the need for research to 
investigate neonatal infection of the newborn of 
pregnant women with sickle cell disease. It is neces-
sary for health investments in Brazil to offer special-
ized support services to women with hemoglobin-
opathies so that they can exercise their sexual and 
reproductive rights without resulting in more risks 
to their health.
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